[Effect of lentinan for advanced prostate carcinoma]

Hinyokika Kiyo. 1994 Feb;40(2):119-23.
[Article in Japanese]

Abstract

A prospective, randomized multi-center study was conducted to assess the clinical effectiveness of Lentinan, an immunomodulatory agent, in the metastatic prostate cancer. Of seventy-five patients enrolled from July 1987 to June 1992, 69 were eligible. All patients received hormonal therapy and chemotherapy using Tegafur p.o. at a dose of 400-800 mg/day. While 33 patients received Lentinan i.m. for at least three months, the other 36 did not. The dose of Lentinan was 2 mg weekly for inpatients and 4 mg every other week for outpatients. The mean age of treated and control patients was 70 (range; 53-83) and 71 (range; 50-86), respectively. The 50% survival length of treated and control patients was 48 and 35 months, respectively. The five-year survival rate of treated patients was 43% according to the Kaplan-Meier method, while that of control patients was 29% (p < 0.05). We conclude that Lentinan is effective in metastatic prostate cancer when incorporated into hormonochemotherapy.

Publication types

  • Clinical Trial
  • English Abstract
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Aged, 80 and over
  • Drug Therapy, Combination
  • Humans
  • Injections, Intramuscular
  • Lentinan / administration & dosage
  • Lentinan / therapeutic use*
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Prospective Studies
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / mortality
  • Survival Rate
  • Tegafur / administration & dosage

Substances

  • Tegafur
  • Lentinan